Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited (SBMFF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
sbmff · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Sino Biopharmaceutical LimitedYou SBMFF | $11.3B | 30.33x | — | $0.13 |
 Akari Therapeutics, Plc AKTX | $18M | N/A | — | -$822.15 |
 Axcella Health Inc. AXLA | $13M | N/A | — | -$1.27 |
 BioCardia, Inc. BCDA | $5M | N/A | — | -$1.23 |
 BioLineRx Ltd. BLRX | $14M | N/A | — | -$0.29 |
 BiondVax Pharmaceuticals Ltd. BVXV | $5M | N/A | — | -$0.20 |
 Can-Fite BioPharma Ltd. CANF | $2M | N/A | — | -$12.02 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Sino Biopharmaceutical Limited (SBMFF) measures how much investors pay for each dollar of the company's trailing earnings. SBMFF's current PE ratio of 30.33x is calculated by dividing its stock price of $0.63 by its TTM earnings per share of $0.13.
Frequently asked questions
SBMFF pe ratio · 6 questionsSBMFF's current PE ratio is 30.33x as of 2026-06-09, based on a stock price of $0.63 and TTM EPS of $0.13. Data sourced from Financial Modeling Prep via SBMFF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Sino Biopharmaceutical Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09